Pfizer Inc. and Eli Lilly & Co. have filed the first nerve growth factor (NGF) inhibitor, tanezumab, with the US Food and Drug Administration for the treatment of pain in patients with moderate-to-severe osteoarthritis. Pfizer confirmed the December filing during the company's fourth quarter sales and earnings call on 28 January.
The path to market for NGF inhibitors has been uncertain because of the challenging safety profile of the drugs, but...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
